Диссертация (Способы коррекции ранних механизмов канцерогенеза в органах репродуктивной системы), страница 33
Описание файла
Файл "Диссертация" внутри архива находится в папке "Способы коррекции ранних механизмов канцерогенеза в органах репродуктивной системы". PDF-файл из архива "Способы коррекции ранних механизмов канцерогенеза в органах репродуктивной системы", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве РУДН. Не смотря на прямую связь этого архива с РУДН, его также можно найти и в других разделах. , а ещё этот архив представляет собой докторскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени доктора медицинских наук.
Просмотр PDF-файла онлайн
Текст 33 страницы из PDF
Altern Med Rev. 2002; 7(2):112-29.191.Lovly C.M. Combating acquired resistance to tyrosine kinaseinhibitors in lung cancer. Am Soc Clin Oncol Educ Book. 2015:e165-73.192.Lushchak V.I. Free radicals, reactive oxygen species, oxidativestresses and their classifications. Ukr Biochem J. 2015; 87(6):11-8.193.Manson M.M., Farmer P.B., Gescher A., Steward W.P.
Innovativeagents in cancer prevention. Recent Results Cancer Res. 2005; 166:257–75.202194.Martin D.A., Bolling B.W. A review of the efficacy of dietarypolyphenols in experimental models of inflammatory bowel diseases.Food Funct. 2015; 6(6):1773-1786.195.Martucci C. P., Fishman J. P450 enzymes of estrogen metabolism.Pharmacology & Therapeutics. 1993; 57(2-3): 237-257;196.Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, BarrettJC, Berchuck A, Futreal PA.
Mutation of the PTEN tumor suppressorgene in endometrial hyperplasias. Cancer Res. 1998; 58(12):2500-3.197.McDonald E.R., el Deiry W.S. Cell cycle control as a basis forcancer drug development. Int. J. Oncol. 2000; 16, 871.198.Meeran S.M., Patel S.N., Li Y., Shukla S., Tollefsbol T.O.Bioactive dietary supplements reactivate ER expression in ER-negativebreast cancer cells by active chromatin modifications. PLoS One 2012;7:e37748.199.Mereles D., Hunstein W. Epigallocatechin-3-gallate (EGCG) forclinical trials: more pitfalls than promises? Int J Mol Sci.2011;12(9):5592-603.200.Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, etal. 5′ CpG island methylation is associated with transcriptional silencingof the tumour suppressor p16/CDKN2/MTS1 in human cancers.
NatMed. 1995; 1:686–692.201.Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., HarshmanK., Tavtigian S., et al (1994) A strong candidate for the breast andovarian cancer susceptibility gene BRCA1. Science 266:66–71.202.Mohan N., Karmakar S., Banik N.L., Ray S.K. SU5416 and EGCGwork synergistically and inhibit angiogenic and survival factors andinduce cell cycle arrest to promote apoptosis in human malignantneuroblastoma SH-SY5Y and SK-N-BE2 cells. Neurochem Res 2011;36(8):1383-96.203203.Molano M., Van den B.A., Plummer M., Weiderpass E., Posso H.,Arslan A., Meijer C.J., Munoz N., Franceschi S.
Determinants ofclearance of human papillomavirus infections in Colombian women withnormal cytology: a population-based, 5-year follow-up study Am. J.Epidemiol., 158 (2003), pp. 486–494.204.Momparler RL. Cancer epigenetics. Oncogene. 2003;22:6479–83.205.Moody C.A., Laimins L.A.
Human papillomavirus oncoproteins:pathways to transformation. Nat Rev Cancer. 2010;10:550–60.206.Moore C, Kohler G, Muller A. The treatment of endometriosis withdienogest. Drugs of Today 1999; 35(C):41-52.207.Mosquera JM, Perner S, Genega EM et al. Characterization ofTMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasiaand potential clinical implications.
Clin Cancer Res 2008; 14: 33803385.208.Mukherjee S., Siddiqui M.A., Dayal S., Ayoub Y.Z., Malathi K.Epigallocatechin-3-gallate suppresses proinflammatory cytokines andchemokines induced by Toll-like receptor 9 agonists in prostate cancercells. J Inflamm Res. 2014; 7:89-101.209.Munoz N., Castellsague X., de Gonzalez A.B., Gissmann L.Chapter 1. HPV in the etiology of human cancer. Vaccine.
2006; 24:1–10.210.MurakamiA.,OhnishiK.Targetmoleculesoffoodphytochemicals: food science bound for the next dimension. Food Funct.2012; 3(5):462-476.211.Nachshon-Kedmi M., Yannai S., Haj A., Fares F.A. Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostatecancer cells. Food Chem Toxicol. 2003; 41(6):745-52.212.Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, SledgeGW Jr. Constitutive activation of NF-kappaB during progression of204breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17:3629–3639.213.Nicholson R.
I., McClelland R. A., Robertson J. F., Gee J. M.Involvement of steroid hormone and growth factor cross-talk inendocrine response in breast cancer. Endocr. Relat. Cancer, 1999. 6: 373387.214.Nihal M., Roelke C.T., Wood G.S. Anti-melanoma effects ofvorinostatincombinationwithpolyphenolicantioxidant(-)-epigallocatechin-3-gallate (EGCG). Pharm Res 2010; 27(6):1103-14.215.Nikitina D., Llacuachaqui M., Sepkovic D., Bradlow H.L., NarodS.A., Kotsopoulos J. The effect of oral 3,3'-diindolylmethanesupplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers.Fam Cancer. 2015, 14(2): 281-286.216.Nilsson I., Hoffmann I.
Cell cycle regulation by the Cdc25phosphatase family. Prog. Cell Cycle Res. 2000; 4, 107.217.Nomelini R. S., de Abreu Ribeiro L. C., Tavares-Murta B. M., AdadS. J., Murta E. F. Production of Nitric Oxide and Expression of InducibleNitric Oxide Synthase in Ovarian Cystic Tumors. Mediators Inflamm.2008; 186584.218.Ohshima H., Bartsch H. Chronic infections and inflammatoryprocesses as cancer risk factors: possible role of nitric oxide incarcinogenesis.MutationResearch/FundamentalandMolecularMechanisms of Mutagenesis, vol.
305, no. 2, pp. 253–264, 1994.219.Orbo A, Nilsen MN, Arnes MS, Pettersen I, Larsen K. Loss ofexpression of MLH1, MSH2, MSH6, and PTEN related to endometrialcancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol2003; 22:141–8.220.Osborne M.P., Bradlow H.L., Wong G.Y.C. and Telang N.T. (1993)Upregulation of estradiol C16α-hydroxylation in human breast tissue: a205potential biomarker of breast cancer risk. J. Natl Cancer Inst., 85, 1917–1920;221.Pal T., Permuth-Wey J., Betts J.A., et al.
BRCA1 and BRCA2mutations account for a large proportion of ovarian carcinoma cases.Cancer 2005; 104(12):2807–16.222.Paltsev M., Kiselev V., Muyzhnek E., Drukh V., Kuznetsov I.,Pchelintseva O. Comparative preclinical pharmacokinetics study of 3,3'diindolylmethane formulations: is personalized treatment and targetedchemoprevention in the horizon? The EPMA Journal. 2013; 4(1):25.223.Paltsev M., Kiselev V., Muyzhnek E., Drukh V., Kuznetsov I.,Pchelintseva O. Safety and tolerability of DIM-based therapy designedas personalized approach to reverse prostatic intraepithelial neoplasia(PIN).
The EPMA Journal. 2014; 5(1): 18.224.Paltsev M, Kiselev V, Drukh V, Muyzhnek E, Kuznetsov I,Andrianova E, Baranovskiy P. First results of the double-blindrandomized placebo-controlled multicenter clinical trial of DIM-basedtherapy designed as personalized approach to reverse prostaticintraepithelial neoplasia (PIN). The EPMA Journal 2016, 7:5.225.Paltsev M., Kiselev V., Drukh V., Muyzhnek E., Kuznetsov I.,Andrianova E., Baranovskiy P. First results of the double-blindrandomized placebo-controlled multicenter clinical trial of DIM-basedtherapy designed as personalized approach to reverse prostaticintraepithelial neoplasia (PIN).
EPMA J. 2016; 7:5.226.Pandey M., Shukla S., Gupta S. Promoter demethylation andchromatin remodeling by green tea polyphenols leads to re-expression ofGSTP1 in human prostate cancer cells. Int J Cancer 2010; 126:2520–2523.227.Parekh T.V., Gama P., Wen X., Demopoulos R., Munger J.S.,Carcangiu M.L., Reiss M., Gold L.I. Transforming growth factor beta206signaling is disabled early in human endometrial carcinogenesisconcomitant with loss of growth inhibition. Cancer Res. 2002;62(10):2778-90.228.Parkin D.M., Pisani P, Muñoz N, Ferlay J.
In: Newton R, Beral V,Weiss RA, eds. Infections and human cancer. Cold Spring Harbor, NY:Cold Spring Harbor Laboratory Press, 1999.229.Pearce C. L. et al. Association between endometriosis and risk ofhistological subtypes of ovarian cancer: a pooled analysis of case–controlstudies. Lancet Oncol.
2012, 13, 385–394.230.Pectasides D., Kamposioras K., Papaxoinis G., Pectasides E.Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008,34(7):603-613.231.Pike M.C., Spicer D.V., Dahmoush L. and Press M.F. (1993)Estrogens, progestrogens, normal breast cell proliferation, and breastcancer risk. Epidemiol.
Rev., 15, 17–35.232.Pines J. Protein kinases and cell cycle control. Semin Cell Biol.1994; 5(6):399-408.233.Pittatore G., Moggio A., Benedetto C., Bussolati B., Revelli A.Endometrial adult/progenitor stem cells: pathogenetic theory and newantiangiogenic approach for endometriosis therapy. Reprod Sci. 2014;21(3):296-304.234.Plu-Bureau G., Lê M.G., Sitruk-Ware R., Thalabard J.C. Cyclicalmastalgia and breast cancer risk: results of a French cohort study.
